| Trial ID: | L3997 |
| Source ID: | NCT01843881
|
| Associated Drug: |
Exendin 9, 39
|
| Title: |
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Exendin 9, 39|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline), The total disposition index equals the product of insulin secretion and insulin sensitivity., Day 1, Day 2 (approximately 2 weeks after day 1) |
|
| Sponsor/Collaborators: |
Sponsor: Adrian Vella | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2012-03
|
| Completion Date: |
2013-12
|
| Results First Posted: |
|
| Last Update Posted: |
2013-12-04
|
| Locations: |
Mayo Clinic, Rochester, Minnesota, 55905, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01843881
|
